Different Response to Roxadustat Treatment for Anemia Between Patients Undergoing Hemodialysis and Peritoneal Dialysis.
Not Applicable
Recruiting
- Conditions
- End Stage Renal Disease
- Registration Number
- JPRN-UMIN000039729
- Lead Sponsor
- Japanese Red Cross Asahikawa Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Malignancy Blood disease that medical doctor considers not appropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The prespecified primary outcome was the average dose of roxadustat during weeks 23 through 27.
- Secondary Outcome Measures
Name Time Method The secondary outcome was the prevalence of subject whose Hb levels increased 1.0 g/dL or 2.0 g/dL in first 4 weeks.